Business
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025 Corporate Sustainability Assessment (CSA). The company was ranked top in its industry and achieved a Top 1% S&P Global CSA Score, marking the fourth consecutive year that WuXi Biologics has received this highest level of distinction.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025 Corporate Sustainability Assessment (CSA). The company was ranked top in its industry and achieved a Top 1% S&P Global CSA Score, marking the fourth consecutive year that WuXi Biologics has received this highest level of distinction.","length":549,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/9d87ac94463d21c5102479e6ceb3f2e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5ERbPvf.wDQ.7N2EYchnZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9d87ac94463d21c5102479e6ceb3f2e5","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2923053/image.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Yearbook aims to highlight individual companies — within a range of industries — that have demonstrated strong corporate sustainability performance, based on their S&P Global 2025 CSA Score. Out of the over 9,200 companies assessed in the 2025 CSA, only 848 companies, across 59 industries, were recognized as the top performers and selected for inclusion in Yearbook 2026.","length":381,"tagName":"p"},{"type":"text","content":"Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "Our strong performance in S&P Global's latest CSA and our inclusion in the Yearbook for the fourth consecutive year reflect WuXi Biologics' steadfast commitment to continuously enhancing our sustainability performance. We are a proven global leader in Green CRDMO, consistently delivering ESG excellence, enabling partners worldwide to fulfill their ESG commitments, and jointly working with all stakeholders to promote responsible practices throughout the entire value chain."","length":581,"tagName":"p"},{"type":"text","content":"As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI),...